Imagenebio Stock Analysis
| IMA Stock | 6.91 0.06 0.88% |
IPO Date 26th of March 2021 | 200 Day MA 13.7515 | 50 Day MA 8.4522 |
At present, ImageneBio's Debt To Equity is projected to increase slightly based on the last few years of reporting. The current year's Debt Equity Ratio is expected to grow to 0.06, whereas Short and Long Term Debt Total is forecasted to decline to about 6.4 M. With a high degree of financial leverage come high-interest payments, which usually reduce ImageneBio's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0611 | Current Value 0.0581 | Quarterly Volatility 1.53845163 |
ImageneBio is overvalued with Real Value of 5.72 and Hype Value of 6.92. The main objective of ImageneBio stock analysis is to determine its intrinsic value, which is an estimate of what ImageneBio is worth, separate from its market price. There are two main types of ImageneBio's stock analysis: fundamental analysis and technical analysis.
The ImageneBio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ImageneBio's ongoing operational relationships across important fundamental and technical indicators.
ImageneBio | Build AI portfolio with ImageneBio Stock |
ImageneBio Stock Analysis Notes
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.33. ImageneBio had not issued any dividends in recent years. The entity had 1:12 split on the 28th of July 2025. To learn more about ImageneBio call Kristin Yarema at 858 345 6265 or check out https://www.inmagenebio.com.ImageneBio Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ImageneBio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ImageneBio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| ImageneBio generated a negative expected return over the last 90 days | |
| ImageneBio has high historical volatility and very poor performance | |
| ImageneBio was previously known as Ikena Oncology and was traded on NASDAQ Exchange under the symbol IKNA. | |
| The company reported the last year's revenue of 3.5 M. Reported Net Loss for the year was (49.23 M) with profit before taxes, overhead, and interest of 4.3 M. | |
| ImageneBio generates negative cash flow from operations | |
| ImageneBio has a frail financial position based on the latest SEC disclosures | |
| About 14.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hughes Owen of 17520 shares of ImageneBio at 1.75 subject to Rule 16b-3 |
ImageneBio Largest EPS Surprises
Earnings surprises can significantly impact ImageneBio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-08 | 2025-03-31 | -0.1919 | -0.17 | 0.0219 | 11 | ||
2024-11-07 | 2024-09-30 | -0.2549 | -0.21 | 0.0449 | 17 | ||
2024-08-09 | 2024-06-30 | -0.36 | -0.28 | 0.08 | 22 |
ImageneBio Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 91.69 M.ImageneBio Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.24) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.33) | (0.32) |
Management Efficiency
As of February 15, 2026, Return On Tangible Assets is expected to decline to -0.24. In addition to that, Return On Capital Employed is expected to decline to -0.27. At present, ImageneBio's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 153 M, whereas Total Assets are forecasted to decline to about 161.7 M. ImageneBio's management efficiency ratios could be used to measure how well ImageneBio manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.35 | 2.47 | |
| Tangible Book Value Per Share | 2.35 | 2.47 | |
| Enterprise Value Over EBITDA | (23.29) | (24.45) | |
| Price Book Value Ratio | 6.79 | 7.13 | |
| Enterprise Value Multiple | (23.29) | (24.45) | |
| Price Fair Value | 6.79 | 7.13 | |
| Enterprise Value | 1 B | 958.6 M |
ImageneBio has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Technical Drivers
As of the 15th of February 2026, ImageneBio retains the Standard Deviation of 3.78, market risk adjusted performance of (0.40), and Risk Adjusted Performance of (0.03). ImageneBio technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.ImageneBio Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ImageneBio middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ImageneBio. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ImageneBio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImageneBio insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImageneBio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImageneBio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hughes Owen 2 days ago Acquisition by Hughes Owen of 17520 shares of ImageneBio at 1.75 subject to Rule 16b-3 | ||
Erin Butler over a month ago Acquisition by Erin Butler of 22500 shares of ImageneBio at 7.11 subject to Rule 16b-3 | ||
Slattery Joseph P over a month ago Acquisition by Slattery Joseph P of 16000 shares of ImageneBio at 5.99 subject to Rule 16b-3 | ||
Slattery Joseph P over three months ago Insider Trading | ||
Marango Jotin over six months ago Disposition of 4630 shares by Marango Jotin of ImageneBio, at 17.16 subject to Rule 16b-3 |
ImageneBio Outstanding Bonds
ImageneBio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ImageneBio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ImageneBio bonds can be classified according to their maturity, which is the date when ImageneBio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| iHeartCommunications 6375 percent Corp BondUS45174HBC07 | View | |
| iHeartCommunications 8375 percent Corp BondUS45174HBD89 | View | |
| iHeartCommunications 475 percent Corp BondUS45174HBG11 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
ImageneBio Predictive Daily Indicators
ImageneBio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ImageneBio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ImageneBio Corporate Filings
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of February 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 6th of January 2026 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 2nd of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 29th of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 22nd of December 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of December 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 19th of November 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
ImageneBio Forecast Models
ImageneBio's time-series forecasting models are one of many ImageneBio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ImageneBio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.ImageneBio Bond Ratings
ImageneBio financial ratings play a critical role in determining how much ImageneBio have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for ImageneBio's borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (3.73) | Unlikely Manipulator | View |
ImageneBio Total Assets Over Time
ImageneBio Assets Financed by Debt
The debt-to-assets ratio shows the degree to which ImageneBio uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.ImageneBio Debt Ratio | 5.81 |
ImageneBio Corporate Bonds Issued
Most ImageneBio bonds can be classified according to their maturity, which is the date when ImageneBio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
ImageneBio Short Long Term Debt Total
Short Long Term Debt Total |
|
About ImageneBio Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ImageneBio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ImageneBio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ImageneBio. By using and applying ImageneBio Stock analysis, traders can create a robust methodology for identifying ImageneBio entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (9.40) | (9.87) | |
| Operating Profit Margin | (9.51) | (9.99) | |
| Net Loss | (9.40) | (9.87) | |
| Gross Profit Margin | 0.80 | 0.84 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding ImageneBio to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Complementary Tools for ImageneBio Stock analysis
When running ImageneBio's price analysis, check to measure ImageneBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImageneBio is operating at the current time. Most of ImageneBio's value examination focuses on studying past and present price action to predict the probability of ImageneBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImageneBio's price. Additionally, you may evaluate how the addition of ImageneBio to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |